Gufic Biosciences Recommends 10% Final Dividend for FY26
Gufic Biosciences Limited's Board has recommended a final dividend of 10% (Re. 0.10 per share) for FY26. This is subject to shareholder approval at the upcoming AGM. The dividend will be paid as per statutory timelines if approved.
A dividend recommendation is generally positive for investors, but its impact is medium as it does not involve significant new business developments or financial performance changes beyond the distribution of profits.
The recommendation of a final dividend is a positive sign for shareholders, indicating the company's profitability and commitment to returning value.
The Board of Directors of Gufic Biosciences Limited, in a meeting held on May 29, 2026, has recommended a Final Dividend of 10%, equivalent to Re. 0.10 per equity share with a face value of Re. 1 each, for the Financial Year ended March 31, 2026. This recommendation is subject to the approval of the shareholders at the upcoming Annual General Meeting (AGM).
If approved by the shareholders, the dividend will be paid within the timelines stipulated by the Companies Act, 2013. The Board meeting commenced at 7:30 p.m. and concluded at 9:05 p.m. on May 29, 2026.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.